赛德纳姆胆病患者的治疗方法和结果:元分析
Michael Eyre1,2, Terrence Thomas3, Emanuela Ferrarin4
1School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
JAMA network open
|April 16, 2024
概括
免疫疗法,特别是皮质类固醇,加快了西登汉胆固醇的消失,降低了复发风险. 抗生素,皮质类固醇和甲在患有赛登汉姆胆病的儿童中促进单相性疾病的发展.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 类风湿病学 类风湿病学
背景情况:
- 赛德纳姆胆固醇是儿童最常见的获得性胆固醇形运动障碍.
- 目前的治疗选择因缺乏高质量的证据而受到限制.
研究的目的:
- 为了评估西登汉姆病原病的临床特征的历史变化.
- 为了确定与胆病持续时间,复发过程和功能结果相关的临床和治疗因素.
主要方法:
- 系统地对已发表的文章进行元分析,从创作开始到2022年11月.
- 包括1479名患者 (1325名从1945年到2022年) 患有西登汉胆固醇症.
- 分析了临床特征,治疗方法,胆病持续时间,复发和功能结果的数据.
主要成果:
- 免疫疗法,特别是皮质类固醇,与更短的胆固醇持续时间有关 (HR 1.51,P=.03).
- 皮质类固醇治疗 (≥1个月) 减少了中位数胆固醇持续时间 (1.2 vs 2.8个月,P=.004).
- 抗生素,皮质类固醇和甲与单相性疾病过程有关 (降低复发风险).
结论:
- 免疫疗法,特别是皮质类固醇,加速了西登汉胆核病的解决.
- 特定的治疗方法,如抗生素,皮质类固醇和甲与单相性疾病过程有关.
- 这些发现支持制定基于证据的西登汉氏胆固醇治疗指南.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183


